Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NanoSanguis is a Polish biotechnology company specializing in the development of synthetic oxygen carriers and advanced organ preservation systems. As a subsidiary of NanoGroup S.A., the company utilizes proprietary nanotechnology to develop 'artificial blood' (NanoRed) that mimics the oxygen-carrying capacity of red blood cells while offering a longer shelf life and universal compatibility. Their portfolio also includes NanoPreserve, a solution designed to extend the viability of organs during transport for transplantation. NanoSanguis focuses on addressing critical gaps in transfusion medicine and transplantology through innovative nanomedicine solutions. The company is a spin-off from the Warsaw University of Technology and maintains strong ties with academic research to drive its product development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NanoSanguis.